Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.

Introduction: The migraine-preventive drug propranolol is efficacious in reducing pain from temporomandibular disorder, suggesting potential modifying or mediating effects of comorbid migraine.

Methods: In this randomized controlled trial, myofascial temporomandibular disorder patients were treated with propranolol or placebo for 9 weeks. The primary endpoint was change in a facial pain index derived from daily symptom diaries.

Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.

Propranolol is a nonselective beta-adrenergic receptor antagonist. A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2b trial enrolled participants aged 18 to 65 years with temporomandibular disorder myalgia to evaluate efficacy and safety of propranolol compared with placebo in reducing facial pain. Participants were randomized 1:1 to either extended-release propranolol hydrochloride (60 mg, BID) or placebo.

A Comparison of Technique Errors using Two Radiographic Intra-oral Receptor-holding Devices.

Purpose: Technological advances in intra-oral receptors have resulted in film-holding devices that may or may not be interchangeable with photostimulable phosphor receptors. This study evaluated the number and types of technique errors that occurred when using PSP receptors with a standard film-holding device and a dual PSP/film-designed device.

Methods: The Rinn XCP-ORA® (Standard) and the Rinn Flip-Ray® PA device (Test) were compared using rectangular collimation.